April 11, 2022

Both Sides of the Coin: Communicating the Impact of Mental Health Equity & ROI

This is some text inside of a div block.

With nearly half of adult Americans experiencing a clinical mental health issue over the past year, it’s clear we need innovative and effective mental health resources to reach people in need. But providing mental health solutions goes far beyond just checking a box, it is paramount to communicate the importance of providing proven mental health care to peers and senior leaders.

In our session at The Conference Board: Communicating Total Rewards Conference, you will hear from renowned mental health equity scholar Dr. Juliette McClendon on creating equitable mental health programs that reach everyone in need, peers, and senior leadership. Johns Hopkins associate professor and health economics researcher Dr. Michael Darden will also break down an in-depth ROI model built for a Fortune 50 employer to explain how to best report cost savings to senior leadership.

Dr. Darden & Dr. McClendon sheds light on the following topics:

  • Communicating how mental health care impacts healthcare costs
  • The connection between the overmedication dilemma and rising costs
  • How to identify gaps in your strategy to significantly lower healthcare costs
  • Expand access to mental health care by effectively aligning incentives and reaching employees during the moment that matters

Watch the replay

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023